Hologic, Inc.

Hologic, Inc.

HOLXNASDAQHealthcare
$76.01
up +0 (+0.00%)

1-Year Price

+13.38% past year
Hologic, Inc. (HOLX) 1-year price chart: up 13.38% from $67.04 on Oct 2025 to $76.01 on Apr 2026. Closing range $65.51 to $76.01.

EquityGlimpse Score

Overall
5.3/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
2

Valuation, profitability, financial health, dividend and sentiment scores for Hologic, Inc. (HOLX) are available to EquityGlimpse members.

Market Cap
16.97B
P/E Ratio
26.88
EPS
$2.49
52W High
$76.07
52W Low
$51.9
Volume
101.96M
Beta
0.7
Dividend Yield
—
Fair value estimate: sign up to see
Is HOLX over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
3.72
Price to Book
3.02
EV/EBITDA
15.57
Free CF per Share
$4.05
Op. CF per Share
$4.65
Debt to Equity
0.52
Gross Margin
61.00%
Net Margin
13.80%

About Hologic, Inc.

Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.

CEO
Paul Malenchini
Industry
Medical - Instruments & Supplies
Employees
7,063
IPO Date
1990-03-01
Country
US
Unlock Full Analysis

Get the complete picture on Hologic, Inc.

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for HOLX and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.